PLT Test Blog

  Memantine, Arbaclofen  and now Bumetanide stumble in clinical trials (also the less well known Balovaptan, which Roche dropped in 2020). Place your bets on Suramin, anyone?   Plus ça change ,  plus  c'est la  même chose The more things change, the more they stay the same The first week of the school year brought two big surprises.  Monty, aged 18 with autism, came top of the class in the math test.  This is a big win for bumetanide treatment, because 9 years ago Monty was effectively innumerate.  With a huge effort by his Assistant, he had learnt how to read and write, but even the most basic maths was beyond him.  That all changed in 2012 thanks to Professor Ben-Ari’s published research on Bumetanide in autism. The sad news that week was that the Phase 3 clinical trial of Bumetanide for autism had been terminated early.    Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing...

  This time the “Professor” wears the Dunce’s cap I had a surprise last month, talking to my son’s 1:1 assistant, this time about maths (or math in US English). Normally I am trying to simplify school academics, and so if something really is not important, like argumentative writing, I am all for skipping over it.   The idea is that Monty, aged 17 with autism, should focus on useful learning that he has a chance of mastering. Monty’s international school follows an English curriculum and in that model you have a choice in some subjects of studying the core or the extended version. So a typical child who wants to become a doctor, or an engineer, will have to follow the extended version of all their subjects, but someone who is going to shift boxes in a warehouse might opt for the core/simplified versions. Most people lie somewhere in between. People with severe autism would not normally follow any of these academic curricula, because it is all way above their heads.   ...